14 Nov 2025 | 3 Mins Read
Marksans Pharma Q2 profit increases amidst revenue growth
Flipitmoney
Drug firm Marksans Pharma Limited reported reported a net profit of ₹98.2 crore for the quarter ended September 2025, up 1.5% from ₹96.7 crore in the same period last year. Revenue grew 12% to ₹720 crore, while EBITDA declined 1.7% to ₹144.7 crore. EPS was ₹2.2. Half-year operating revenue increased 8.8% to ₹1,340.4 crore.